{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:15:59Z","timestamp":1784546159741,"version":"3.55.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Perinatology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clp.2020.11.002","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T18:04:18Z","timestamp":1613066658000},"page":"15-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Neonatal Leukemia"],"prefix":"10.1016","volume":"48","author":[{"given":"Patrick A.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clp.2020.11.002_bib1","series-title":"SEER cancer statistics review, 1975-2017","year":"2020"},{"issue":"2","key":"10.1016\/j.clp.2020.11.002_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2005-07-3011","article-title":"Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group","volume":"108","author":"Hilden","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clp.2020.11.002_bib3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/leu.2011.267","article-title":"Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report","volume":"26","author":"Creutzig","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clp.2020.11.002_bib4","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1182\/blood.V87.7.2870.bloodjournal8772870","article-title":"Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age","volume":"87","author":"Behm","year":"1996","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clp.2020.11.002_bib5","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.clp.2020.11.002_bib6","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.clp.2020.11.002_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.clp.2020.11.002_bib8","doi-asserted-by":"crossref","first-page":"13950","DOI":"10.1073\/pnas.94.25.13950","article-title":"Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots","volume":"94","author":"Gale","year":"1997","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"6427","key":"10.1016\/j.clp.2020.11.002_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/363358a0","article-title":"In utero rearrangements in the trithorax-related oncogene in infant leukaemias","volume":"363","author":"Ford","year":"1993","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.clp.2020.11.002_bib10","first-page":"2542","article-title":"Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion","volume":"61","author":"Alexander","year":"2001","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.clp.2020.11.002_bib11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1158\/1055-9965.EPI-04-0602","article-title":"Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group","volume":"14","author":"Spector","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"10.1016\/j.clp.2020.11.002_bib12","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1073\/pnas.070061297","article-title":"Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia","volume":"97","author":"Strick","year":"2000","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"13","key":"10.1016\/j.clp.2020.11.002_bib13","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1182\/blood-2001-12-0264","article-title":"Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children","volume":"100","author":"Smith","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clp.2020.11.002_bib14","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1073\/pnas.061408298","article-title":"Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia","volume":"98","author":"Wiemels","year":"2001","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"1","key":"10.1016\/j.clp.2020.11.002_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/pbc.24131","article-title":"Genetic variants modify susceptibility to leukemia in infants: a Children's Oncology Group report","volume":"60","author":"Ross","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.clp.2020.11.002_bib16","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/leu.2013.367","article-title":"Excess congenital non-synonymous variation in leukemia-associated genes in MLL- infant leukemia: a Children's Oncology Group report","volume":"28","author":"Valentine","year":"2014","journal-title":"Leukemia"},{"issue":"1\u20132","key":"10.1016\/j.clp.2020.11.002_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/10428199409051677","article-title":"The role of immunophenotype in acute lymphoblastic leukemia of infant age","volume":"15","author":"Basso","year":"1994","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.clp.2020.11.002_bib18","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.clp.2020.11.002_bib19","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clp.2020.11.002_bib20","first-page":"407","article-title":"Revised risk stratification criteria for children with newly diagnosed acute myeloid leukemia: a report from the Children's Oncology Group","volume":"130","author":"Cooper","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clp.2020.11.002_bib21","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clp.2020.11.002_bib22","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/sj.leu.2404903","article-title":"Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group","volume":"21","author":"Tomizawa","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clp.2020.11.002_bib23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/leu.2013.280","article-title":"Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements","volume":"28","author":"Lorenzo","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clp.2020.11.002_bib24","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.3324\/haematol.2014.122119","article-title":"Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities","volume":"101","author":"Linden","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clp.2020.11.002_bib25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"de Rooij","year":"2017","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.clp.2020.11.002_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1525","article-title":"Origins of leukaemia in children with Down syndrome","volume":"5","author":"Hitzler","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.clp.2020.11.002_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.22266","article-title":"Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol","volume":"54","author":"Hempel","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.clp.2020.11.002_bib28","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/pbc.21925","article-title":"Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia","volume":"52","author":"Lonnerholm","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.clp.2020.11.002_bib29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/pbc.25311","article-title":"Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group","volume":"62","author":"Salzer","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.clp.2020.11.002_bib30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08851.x","article-title":"Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial","volume":"155","author":"Gibson","year":"2011","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clp.2020.11.002_bib31","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/sj.leu.2401818","article-title":"Late effects in survivors of infant leukemia","volume":"14","author":"Leung","year":"2000","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.clp.2020.11.002_bib32","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.clp.2020.11.002_bib33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2017-01-762336","article-title":"Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531","volume":"130","author":"Guest","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clp.2020.11.002_bib34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/asheducation-2013.1.601","article-title":"Does hematopoietic stem cell transplantation benefit infants with acute leukemia?","volume":"2013","author":"Sison","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"15","key":"10.1016\/j.clp.2020.11.002_bib35","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2010-03-273532","article-title":"Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study","volume":"116","author":"Mann","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clp.2020.11.002_bib36","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/leu.2009.17","article-title":"Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol","volume":"23","author":"Van der Velden","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clp.2020.11.002_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2018-04-785980","article-title":"How I treat infant leukemia","volume":"133","author":"Brown","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clp.2020.11.002_bib38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/asheducation-2016.1.598","article-title":"Myelodysplastic and myeloproliferative disorders of childhood","volume":"2016","author":"Hasle","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"10.1016\/j.clp.2020.11.002_bib39","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile myelomonocytic leukemia: who's the driver at the wheel?","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clp.2020.11.002_bib40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/asheducation-2018.1.307","article-title":"JMML genomics and decisions","volume":"2018","author":"Niemeyer","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"10.1016\/j.clp.2020.11.002_bib41","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clp.2020.11.002_bib42","first-page":"3534","article-title":"Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clp.2020.11.002_bib43","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2004-05-1944","article-title":"Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS\/EBMT trial","volume":"105","author":"Locatelli","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clp.2020.11.002_bib44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pbc.25342","article-title":"Phase II\/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group","volume":"62","author":"Stieglitz","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.clp.2020.11.002_bib45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11899-016-0338-x","article-title":"Transient abnormal myelopoiesis and AML in Down syndrome: an update","volume":"11","author":"Bhatnagar","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"10.1016\/j.clp.2020.11.002_bib46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.siny.2012.02.010","article-title":"Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome","volume":"17","author":"Roy","year":"2012","journal-title":"Semin Fetal Neonatal Med"},{"issue":"2","key":"10.1016\/j.clp.2020.11.002_bib47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bjh.15390","article-title":"Guidelines for the investigation and management of transient leukaemia of Down syndrome","volume":"182","author":"Tunstall","year":"2018","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.clp.2020.11.002_bib48","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","article-title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971","volume":"118","author":"Gamis","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clp.2020.11.002_bib49","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-12-3904","article-title":"Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis","volume":"101","author":"Mundschau","year":"2003","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clp.2020.11.002_bib50","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2013-07-515148","article-title":"GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clp.2020.11.002_bib51","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.clp.2020.11.002_bib52","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-03-491936","article-title":"Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome","volume":"122","author":"Nikolaev","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clp.2020.11.002_bib53","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-10-118810","article-title":"Treatment and prognostic impact of transient leukemia in neonates with Down syndrome","volume":"111","author":"Klusmann","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clp.2020.11.002_bib54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1535-6108(03)00003-5","article-title":"Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification","volume":"3","author":"Armstrong","year":"2003","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.clp.2020.11.002_bib55","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood-2003-02-0418","article-title":"FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy","volume":"103","author":"Taketani","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clp.2020.11.002_bib56","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2004-06-2498","article-title":"FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression","volume":"105","author":"Brown","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clp.2020.11.002_bib57","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/sj.leu.2404277","article-title":"Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner","volume":"20","author":"Brown","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clp.2020.11.002_bib58","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2004-09-3667","article-title":"Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia","volume":"106","author":"Stam","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clp.2020.11.002_bib59","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1038\/leu.2012.161","article-title":"Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia","volume":"26","author":"Chillon","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clp.2020.11.002_bib60","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2007-05-091934","article-title":"Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia","volume":"110","author":"Stam","year":"2007","journal-title":"Blood"},{"issue":"Supplement S3","key":"10.1016\/j.clp.2020.11.002_bib61","first-page":"S7","article-title":"SIOP 2016 scientific programme+index","volume":"63","author":"Brown","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"10.1016\/j.clp.2020.11.002_bib62","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1182\/blood-2009-09-243634","article-title":"Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting","volume":"115","author":"Schafer","year":"2010","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clp.2020.11.002_bib63","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1182\/blood-2009-06-227660","article-title":"Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options","volume":"114","author":"Stumpel","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clp.2020.11.002_bib64","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2012.07.013","article-title":"Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia","volume":"49","author":"Stumpel","year":"2013","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.clp.2020.11.002_bib65","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2010.282","article-title":"Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale","volume":"25","author":"Stumpel","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clp.2020.11.002_bib66","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjh.12205","article-title":"MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR 4 antagonism","volume":"160","author":"Sison","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clp.2020.11.002_bib67","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1541-7786.MCR-13-0114","article-title":"Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML","volume":"11","author":"Sison","year":"2013","journal-title":"Mol Cancer Res"},{"issue":"19","key":"10.1016\/j.clp.2020.11.002_bib68","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.18632\/oncotarget.2407","article-title":"Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition","volume":"5","author":"Sison","year":"2014","journal-title":"Oncotarget"},{"issue":"31","key":"10.1016\/j.clp.2020.11.002_bib69","doi-asserted-by":"crossref","first-page":"30902","DOI":"10.18632\/oncotarget.5094","article-title":"POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL","volume":"6","author":"Sison","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.clp.2020.11.002_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26414","volume":"64","author":"Cooper","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"36","key":"10.1016\/j.clp.2020.11.002_bib71","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.clp.2020.11.002_bib72","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.clp.2020.11.002_bib73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"issue":"25","key":"10.1016\/j.clp.2020.11.002_bib74","doi-asserted-by":"crossref","first-page":"6912","DOI":"10.1182\/blood-2011-02-334359","article-title":"DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis","volume":"117","author":"Nguyen","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clp.2020.11.002_bib75","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2012-11-465120","article-title":"Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l","volume":"121","author":"Deshpande","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clp.2020.11.002_bib76","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clp.2020.11.002_bib77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.clp.2020.11.002_bib78","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.V124.21.387.387","article-title":"The DOT1L inhibitor EPZ-5676: safety and activity in relapsed\/refractory patients with MLL-rearranged leukemia","volume":"124","author":"Stein","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clp.2020.11.002_bib79","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V126.23.3792.3792","article-title":"Preliminary report of the phase 1 study of the DOT1L inhibitor, pinometostat, EPZ-5676, in children with relapsed or refractory MLL-r acute leukemia: safety, exposure and target inhibition","volume":"126","author":"Shukla","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clp.2020.11.002_bib80","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.clp.2020.11.002_bib81","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/0008-5472.CAN-06-2369","article-title":"Interaction of MLL amino terminal sequences with menin is required for transformation","volume":"67","author":"Caslini","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.clp.2020.11.002_bib82","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.clp.2020.11.002_bib83","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A\u00a0menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.clp.2020.11.002_bib84","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1365-2141.2008.07100.x","article-title":"Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation","volume":"141","author":"Robinson","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clp.2020.11.002_bib85","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/pbc.22760","article-title":"Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement","volume":"56","author":"Jayanthan","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.clp.2020.11.002_bib86","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.clp.2020.11.002_bib87","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"}],"container-title":["Clinics in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510820301299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095510820301299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:57:52Z","timestamp":1758815872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095510820301299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0095510820301299"],"URL":"https:\/\/doi.org\/10.1016\/j.clp.2020.11.002","relation":{},"ISSN":["0095-5108"],"issn-type":[{"value":"0095-5108","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neonatal Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinics in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clp.2020.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}